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1. Introduction 
Allogeneic hematopoietic stem cell transplantation (HSCT) with some graft sources such as 
bone marrow (BM), mobilized peripheral blood (PB) and cord blood (CB) offers the only 
curative potential for many patients with high risk hematological malignancies, particularly 
acute leukemia. Although BM from human leukocyte antigen (HLA)–identical related 
donors within immediate families is a frontline graft source for this treatment, an alternative 
stem cell source has increasingly provided for patients lacking HLA-identical related 
donors. Recently, CB has been considered an acceptable alternative to source of stem cells in 
unrelated allogeneic HSCT for pediatric and adult patients without HLA–identical related 
or unrelated donors. This review focuses on clinical results of cord blood transplantation 
(CBT) including factors associated with transplantation outcomes and clinical comparison 
studies of CBT and other sources of allogeneic HSCT in adults with acute leukemia. Several 
strategies including a reduced intensity regimen and double CB units from different donors 
have been developed to overcome the limited cell dose in CBT for adults. Moreover, to 
reflect the current encouraging reports and potential starategies, the possibility of CB for 
immune therapy in the setting of allogeneic HSCT is also discussed. 
More than 50 years ago in 1957, Thomas et al. reported the first experience with allogeneic 
bone marrow transplantation (BMT) in patients with advanced leukemia (Thomas et al., 
1957) and since then allogeneic HSCT has been a curative treatment for patients with both 
malignant and non-malignant hematologic diseases (Appelbaum, 2007). The initial purpose 
of infusion of BM was rescue of the BM function against myeloablaitive dose of radiation 
and/or chemotherapy, which generates killing of leukemia cells. Thereafter, the evidence of 
a graft-versus-leukemia (GVL) effect, which is mediated by both host histocompatibility 
antigen-specific T cells, tumor antigen-specific T cells and Natural killer (NK) cells against 
leukemia cells, confirmed that allogeneic HSCT is also the only form of cancer immune 
therapy for leukemia refractory to chemotherapy (Jenq & van den Brink, 2010). 
Although allogeneic HSCT was initially limited to the approximately two-thirds of patients 
with a suitably HLA–identical related donor, an alternative stem cell source has increasingly 
provided for patients lacking HLA-identical related donors. After Broxmeyer et al. 
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demonstrated that CB included a number of hematopoietic stem/progenitor cells that 
would be capable of hematopoietic reconstitution in humans (Broxmeyer et al., 1989), the 
first CBT was reported by Gluckman et al. in a child with Fanconi anemia using CB from his 
HLA-matched sister in 1988 (Gluckman et al., 1989). Since the first success of CBT, 
Rubinstein et al. established the first unrelated CB bank at the New York Blood Center in 
1992 (Rubinstein et al., 1993, 1995). Since then, CB banks have been developed worldwide 
for not only related but also unrelated CBT with more than 3000 CB transplants performed 
annually around the world (Foeken et al., 2010). In 1996, Laporte et al. reported a first adult 
patient with chronic myelogenous leukemia (CML) who underwent the transplantation of 
CB from unrelated donor (Laporte et al., 1996). Earlier, most patients were pediatric 
(Kurtzberg et al., 1996; Wagner et al., 1996; Rubinstein et al., 1998) because of the relatively 
lower cell doses in CB grafts, followed by an increased number of adult CBT (Laughlin et al., 
2001; Sanz et al., 2001), showing that CB could effectively restore hematopoiesis with 
acceptable incidence of severe graft-versus-host disease (GVHD). Recently, CB has been 
considered an acceptable alternative to source of hematopoietic stem cells (HSCs) in 
unrelated allogeneic HSCT for pediatric and adult patients without HLA–identical related 
or unrelated donors. 
In comparison with other sources of allogeneic HSCT, CBT has several clinical advantages, 
including rapid and convenient availability because of the stored CB units in the CB bank, 
less stringent criteria for HLA matching for donor-recipient selection, lower incidence of 
GVHD without compromising GVL effects, low risk of viral transmitting and the absence of 
risk for donors, whereas limited cell dose remains the main disadvantage in CBT. The 
limited cell dose might contribute to higher incidence of graft failure and delayed neutrophil 
recovery, which are mostly due to higher risk of bacterial and fungal infections in the early 
phase after CBT (Narimatsu et al., 2005; Parody et al., 2006; Tomonari et al., 2007; Yazaki et 
al., 2009; Miyakoshi et al., 2007; van Burik & Brunstein, 2007; Delaney et al., 2009). Moreover, 
viral infections may be more common after CBT than after BMT/PBSCT, essentially 
attributable to delayed immune reconstitutions after CBT (Tomonari et al., 2003a, 2003b, 
2004, 2005; Parody et al., 2006; van Burik & Brunstein, 2007; Delaney et al., 2009). The 
advantages and disadvantages of CB as a source of allogeneic HSCT are shown in Table1. 
2. Clinical results in adults with acute leukemia 
2.1 Factors associated with clinical outcomes in CBT 
It is known that larger total nucleated cell (TNC) dose improve faster hematopoietic 
recovery, decrease treatment-related mortality (TRM) and survival of CBT recipients 
(Rubinstein et al., 1998; Laughlin et al., 2001; Gluckman et al., 2004; Arcese et al., 2006; 
Barker et al., 2010). Recent New York Blood Center analysis of 1061 recipients of single-unit 
myeloablative CBT for leukemia or myelodysplastic syndrome (MDS) demonstrated that 
TNC dose and HLA-match each affected survival via their effect on TRM (Barker et al., 
2010). These analysis recommended the best transplantation outcomes were in recipients of 
6 of 6 units regardless of precryopreservation TNC dose (median, 4.0×107cells/kg), 
indicating that HLA match at HLA-A and -B antigens and -DRB1 alleles, rather than high 
TNC dose, was the more favorable graft characteristic. Further, recipients of 4 of 6 units 
required a precryopreservation TNC ≥ 5.0×107cells/kg to achieve comparable TRM and 
disease-free survival (DFS) to that of recipients of 5 of 6 units with a TNC ≥ 2.5×107cells/kg. 
In contrast, the minimum cell dose is not clear for adults who have indications for CBT. In a 
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 CB BM/ mobilized PB 
Advantages   
Availability of grafts Rapid (less than one 
month) 
Prolonged (a few months) 
Requirement of HLA matching 4/6 or higher 6/6 
Risk of severe GVHD Lower risk Higher risk 
Risk of viral transmission Very low risk Low Risk 
Risk of donor No risk Low Risk 
Disadvantages   
Number of infused nucleated cells Limited cell dose Higher cell dose 
Speed of hematopoietic recovery Delay Faster than CB 
Risk of infection after HSCT Higher risk than 
BM/PB 
High risk 
Possibility of donor lymphocyte 
infusion or second HSCT from same 
donor 
Impossible Possible 
Potential of congenital disease 
transmission 
Low potential Few potential 
CB indicates cord blood; BM, bone marrow; PB, peripheral blood; HLA, human leukocyte antigen; 
GVHD, graft-versus-host disease; HSCT, hematopoietic stem cell transplantation.  
Table 1. Advantages and disadvantages of CB as a source of hematopoietic stem cell 
compared with BM or mobilized PB 
Japanease study, patients receiving CB grafts containing 1-2×107cells/kg were observed and 
four of seven low-cell-dose recipients survived with longer follow-up (Takahashi et al., 
2006). Those results indicated that CB grafts containing fewer than 2×107cells/kg may be 
useful for cases for which no grafts with higher cell doses or other stem cell sources are 
available. On the other hands, Wagner et al. demonstrated that a correlation between higher 
CD34+ cell dose and rate of engraftment in pediatric patients (Wagner et al., 2002). 
However, CD34+ cell measurement is not standardized between CB banks.  
HLA compatibility was thought to be another key factor in CBT outcome, as with other stem 
cell sources. Several studies have shown that HLA mismatch at HLA-A, -B antigens and -
DRB1 alleles leads to delayed engraftment, increased severity of acute GVHD, increased 
TRM and decreased survival (Rubinstein et al., 1998; Gluckman et al., 2004; Barker et al., 
2010; Delaney & Ballen, 2010). Although increasing the number of HLA mismatching might 
be associated with decreased relapse risk in patients with leukemia, suggested GVL effect 
increased in HLA-mismatched CBT, HLA-mismatch does not offer any benefit in DFS 
(Barker et al., 2010). In general, recommended CB unit is ≥ 4 of 6 HLA-A, -B antigen and -
DRB1 allele matched with the patient.  
The role of anti-HLA antibodies in graft rejection of organ transplantations has been 
analyzed extensively. The majority of CBTs have HLA disparities. Takanashi et al. reported 
the impact that patients' pretransplantation anti-HLA antibodies have on the outcome of 
myeloablative CBT using single unit (Takanashi et al., 2010). Of 386 cases tested, 89 (23.1%) 
were anti-HLA antibody-positive. Of the 89 antibody-positive cases, 20 patients had 
specificity against the CB HLA. Cumulative incidence (CI) of neutrophil recovery 60 days 
after transplantation was 83% for the antibody-negative group, 73% for antibody-positive, 
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but only 32% for the positive against CB (p<0.0001). These data suggested that patients' 
pretransplantation anti-HLA antibodies should be tested and considered in the selection of 
CB. 
The logistics of the selection of CB grafts, including how to select double-unit grafts, for 
transplantation are as practiced by each centers (Shaw et al., 2009; Rocha & Gluckman, 2009; 
Barker et al., 2011). 
2.2 Comparisons of unrelated donor cord blood and other stem cell sources 
After Laughlin et al. initially reported the feasibility in adult patients receiving 
myeloablative CBT (Laughlin et al., 2001), two registration-based and one single-
institution studies comparing both CBT and BMT from unrelated donor in adult patients 
with acute leukemia after myeloablative conditioning were published (Laughlin et al., 
2004; Rocha et al., 2004; Takahashi et al., 2004). Selected studies are detailed in Table 2. 
These studies demonstrated that hematological recovery after CBT was slower when 
compared to unrelated BMT and that the incidence of severe acute and chronic GVHD 
was significantly lower after CBT than after BMT. However, the DFS rate and relapse 
incidence in CB recipients were not inferior to those in BM recipients. In a two meta-
analysis using pooled comparative data from the above three reports, Hwang et al. 
reported that TRM (pooled estimate 1.04, 95% confidence interval [CI]=0.52-2.08; p=0.91) 
and DFS (pooled estimate 0.59, 95%CI=0.18-1.96; p=0.39) were not statistically different in 
adults (Hwang et al., 2007), whereas Wang et al. reported overall survival (OS) after CBT 
(hazard ratio [HR] 1.26, 95%CI=1.13-1.40) was statistically inferior in adults (Wang et al., 
2010). Recently, Eapen et al. reported a comparative analysis of CBT from unrelated donor 
with BMT or peripheral blood stem cell transplantation (PBSCT) from unrelated donors in 
1525 adult patients with acute leukemia after myeloablative conditioning (Eapen et al., 
2010). 165 received CBT, 888 received PBSCT, and 472 received BMT. Leukaemia-free 
survival (LFS) in patients after CBT was comparable with that after 8/8 and 7/8 allele-
matched PBSCT or BMT. However, TRM was higher after CBT than after 8/8 allele-
matched PBSCT (HR 1.62, 95%CI=1.18-2.23; p=0.003) or BMT (HR 1.69, 95%CI=1.19-2.39; 
p=0.003). Grades II to IV acute and chronic GVHD were lower in CBT recipients 
compared with allele-matched PBSCT (HR 0.57, 95%=0.42-0.77; p=0.002 and HR 0.38, 
95%CI=0.27-0.53; p=0.003, respectively), while the incidence of chronic, but not acute 
GVHD, was lower after CBT than after 8/8 allele-matched BMT (HR 0.63, 95%CI=0.44-
0.90; p=0.01).  
Data comparing both CBT and BMT or PBSCT from related donors in adult patients is 
equally encouraging. We studied the outcomes of 171 adults with hematological 
malignancies who received unrelated CBT as a primary unrelated stem cell source (n=100), 
or BMT or PBSCT from related donors (n=71;55 BMT and 16 PBSCT) followed by 
myeloablative regimens (Takahashi et al., 2007). Significant delays in engraftment occurred 
after CBT. The CIs of grades III to IV acute and extensive type chronic GVHD among CBT 
recipients were significantly lower than those among BMT/PBSCT recipients. Multivariate 
analysis demonstrated no apparent differences in TRM (9% in CBT and 13% in 
BMT/PBSCT), relapse (17% in CBT and 26% in BMT/PBSCT) and DFS (70% in CBT and 
60% in BMT/PBSCT). Unrelated CB could be as safe and effective a stem cell source as 
related BM or mobilized PB for adult patients when it is used as a primary unrelated stem 
cell source. 
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Reference Disease
HSC source: 
number of 
patients 
Median 
age 
(years) 
Median 
time to 
ANC≥500/μl 
(days) 
Incidence 
of grade II-
IV acute 
GVHD (%)
Incidence 
of TRM 
(year) 
Relapse 
rate 
(year) 
Probablity 
of DFS 
(year) 
Laughlin 
et al.,2004 
AML 
ALL 
CML 
MDS 
CB:150 
16-60 
27 41 63% 17% 23% (3) 
uBM:367 20 48 46% 23% 33% (3) 
MuBM:83 18 51 65% 14% 19% (3) 
Roche et 
al.,2004 
AML 
ALL 
CB:98 25 26 26 44% (2) 23% (2) 33% (2) 
uBM:584 32 19 39 38% (2) 23% (2) 38% (2) 
Takahashi 
et al.,2004 
AML 
ALL 
Other 
CB:68 36 22 30 9% (1) 16% (2) 74% (2) 
uBM:39 26 18 30 29% (1) 25% (2) 44% (2) 
Takahashi 
et al.,2007 
AML 
ALL 
Other 
CB:100 37 22 52 9% (1) 17% (3) 70% (3) 
rBM/PB:71 40 17 52 13% (1) 26% (3) 60% (3) 
Kumar et 
al.,2008 
ALL138
CB:19 19 NA 32* 34% (3) 5% (3) 61% (3) 
rBM:90 90 NA 20* 44% (3) 26% (3) 27% (3) 
uBM:15 15 NA 10* 53% (3) 20% (3) 13% (3) 
MuBM:14 14 NA 7* 86% (3) 0% (3) 14% (3) 
Atsuta et 
al.,2009 
AML:484
CB:173 38 NA 32 30% (1) 31% (2) 36% (2) 
uBM:311 38 NA 35 19% (1) 24% (2) 54% (2) 
ALL:336
CB:114 34 NA 28 21% (1) 31% (2) 45% (2) 
uBM:222 32 NA 42 23% (1) 24% (2) 51% (2) 
Eapen et 
al.,2010 
AML 
ALL 
CB:165 28 24 30 37% (2) 1.00** 1.00** 
uBM:332 
39 19 
39 22% (2) 0.85** 1.15** 
MuBM:140 46 34% (2) 0.84** 0.93** 
uPB:632 
33 14 
48 24% (2) 0.85** 1.12** 
MuPB:256 52 38% (2) 0.91** 0.91** 
CBT indicates cord blood transplantation; AML, acute myeloid leukemia; ALL, acute lymphoblastic 
leukemia; CML, chronic myelogenous leukemia; MDS, myelodysplastic syndrome; HSC, hematopoietic 
stem cell; CB, cord blood; uBM, unrelated bone marrow; MuBM, mismatched unrelated bone marrow; 
rBM/PB, related bone marrow/ peripheral blood; uPB, unrelated peripheral blood; MuPB, mismatched 
unrelated peripheral blood; ANC, absolute neutrophil count; NA, information not available; GVHD, 
graft-versus-host disease; TRM, treatment-related mortality; DFS, disease-free survival. 
* The incidence of grade III-IV acute GVHD was shown in this study. 
**Results were expressed as hazard ratios (the relative rate of occurrence of the event with CB as 
compared with another). 
Table 2. Published comparative reports of CBT and other stem cell sources in adults with 
acute leukemia 
Another alternative option for patients lacking an HLA-matched related and unrelated donor 
is allogeneic HSCT from haploidentical related donors. Almost all patients will have available 
to them a haploidentical family member donor. However, randomized study has never been 
published the comparison of outcomes of haploidentical HSCT and CBT for adult patients 
with leukemia (Ballen & Spitzer, 2011). Clinical study comparing haploidentical HSCT to CBT 
are warranted. 
Reports of disease-specific outcomes for adult patients with acute myeloid leukemia (AML) 
or acute lymphoblastic leukemia (ALL) after CBT are still limited (Ooi et al., 2004, 2008, 
2009; Konuma et al, 2009a). Kumar et al. studied the relative impact of donor source on 
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outcomes following myeloablative HSCT for 138 adult patients with ALL (Kumar et al., 
2008). When compared with unrelated BMT, OS with CBT was better (relative risk [RR] 0.3, 
95%CI=0.1-0.7; p=0.01). Recently, Atsuta et al. reported a disease-specific comparison of CBT 
and HLA allele-matched unrelated BMT among 484 patients with AML (AML; 173 CB and 
311 BM) and 336 patients with ALL (ALL; 114 CB and 222 BM) who received myeloablative 
transplantations (Atsuta et al., 2009). In multivariate analyses, among AML cases, lower OS 
(HR 1.5, 95%CI=1.0-2.0; p=0.028) and LFS (HR 1.5, 95%CI=1.1-2.0; p=0.012) were observed in 
CB recipients. The relapse rate did not differ between the 2 groups of AML (HR 1.2, 
95%CI=0.8-1.9; p=0.38). However, the TRM rate showed higher trend in CB recipients (HR 
1.5, 95%CI=1.0-2.3; p=0.085). In ALL, there was no significant difference between the groups 
for relapse (HR 1.4, 95%CI=0.8-2.4; p=0.19) and TRM (HR 1.0, 95%CI=0.6-1.7; p=0.98), which 
contributed to similar OS (HR 1.1, 95%CI=0.7-1.6; p=0.78) and LFS (HR 1.2, 95%CI=0.9-1.8; 
p=0.28).  
Taken together, their results showed that CBT is feasible in adults when a CB unit contains a 
higher number of cells and when a transplant is needed urgently, and should be considered 
an option as an allogeneic stem cell source for patients lacking an HLA-matched unrelated 
donor. The results also showed that despite increased HLA disparity, CBT from unrelated 
donors is promising in adults with acute leukemia.  
3. Improvement methods of engraftment and delay hematopoietic recovery 
The relatively low number of HSCs and progenitors per one unit is a main limitation of CB 
instead of BM or mobilized PB as a stem cell source for HSCT, especially in adults. The low 
cell dose available for HSCT might contribute to higher incidence of graft failure, delayed 
hematopoietic recovery and delayed immune reconstitution. As a consequence, it is well 
known that transplanted cell dose is associated with TRM and survival after CBT. There 
have been several developing strategies to overcome the obstacle of low number of cell dose 
using CB as a stem cell source for transplantation, especially in adults. 
3.1 Ex vivo expansion of cord blood 
To improve limited cell dose contained in CB grafts, one attractive option is ex vivo 
expansion of CB which has been shown to have greater proliferative and self-renewal 
capacity when compared to the other sources of HSCs (Broxmeyer et al., 1992; Hows et al., 
1992). Initial CB expansion attempts have used a variety of cytokines, such as stem cell 
factor (SCF), fms-like tyrosine kinase 3 (flt-3) ligand, thrombopoietin (TPO) and G-CSF 
(granulocyte colony-stimulating factor), reagents, such as polyamine copper chelator, 
tetraethylenepentamine (TEPA), and mesenchymal stem cells (MSCs), to cell culture. Several 
clinical studies were investigated, but have not achieved clinically relevant effects (Shpall et 
al., 2002; de Lima et al., 2008, 2010; Jaroscak et al., 2003; Delaney et al., 2010; Kelly et al., 
2009) (Table 3). Delancy et al. report the development of a clinically relevant Notch-
mediated ex vivo expansion system for CB CD34+ cells and the phase I study involving 
transplantation of a non-manipulated unit along with CB progenitors from a second CB unit 
that have undergone Notch-mediated ex vivo expansion in 10 patients with acute leukemia 
(Delaney et al., 2010). After ex vivo expansion, there was an average fold expansion of 
CD34+ cells of 164 and an average fold expansion of total cell numbers of 562. The infused 
CD34+ cell dose derived from the expanded CB graft averaged 6×106 CD34+cells/kg versus 
0.24 ×106 CD34+cells/kg (p=0.0004) from the non-manipulated CB graft. Time to absolute 
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neutrophil count (ANC) ≥500/μl was shortened significantly with a median time of 16 days 
(range, 7–34 days) compared with cohort of 20 patients undergoing double CBT with a 
median time of 26 days (range, 16–48 days; p= 0.002), despite loss of contribution to 
engraftment from the expanded cell graft. This is highly suggestive of a facilitating effect of 
the cultured cells in promoting engraftment from the non-manipulated CB unit. This is the 
first instance of rapid engraftment derived from ex vivo expanded CB stem/progenitor cells 
in humans. 
 
Expansion 
type 
Reference
Number 
of 
patients
Cytokines
Days in 
culture
TNC fold 
expansio
n (folds)
CD34+ 
fold 
expansio
n (folds)
Median 
time to 
ANC≥500
/μl (days)
Median 
time to 
PLT≥2000
0/μl 
(days) 
Incidence 
of each 
grade acute 
GVHD (%) 
Survival 
(duration 
of follow 
up) 
Liquid 
culture 
Shpall et 
al.,2002 
37 
SCF,G-
CSF,TPO 
10 56 4 28 106 
II to 
IV:67% 
III to 
IV:40% 
32%  
(30 
months) 
de Lima et 
al.,2008 
10 
SCF,Flt3L,
G-
CSF,TPO,IL
-6+TEPA 
21 219 6 30 48 
II to 
IV:44% 
III to IV:0% 
30%  
(180 days) 
Delany et 
al.,2010 
10 
Notch 
ligand,SCF,
Flt3L,TPO,I
L-6,IL-3 
16 562 164 16 NA 
II to IV:9/9 
III to 
IV:1/9 
7/10 alive 
(1 year) 
Stromal 
co-culture 
de Lima et 
al.,2010 
32 
SCF,Flt3L,
G-
CSF,TPO+
MSCs 
14 40 14 15 40 
II to 
IV:50% 
III to 
IV:16% 
40%  
(1 year) 
Continu-
ous 
perfusion 
system 
Jaroscak et 
al.,2003 
27 
PIXY321,Flt
3L,EPO 
12 2.4 0.5 22 71 
II to 
IV:36% 
III to 
IV:22% 
39%  
(41 
months) 
CBT indicates cord blood transplantation; CB, cord blood; SCF, stem cell factor; G-CSF, granulocyte 
colony-stimulating factor; TPO, thrombopoietin; Flt3L, fms-like tyrosine kinase 3 ligand; IL, interleukin; 
TEPA, tetraethylenepentamine; MSCs, mesenchymal stem cells; PIXY321, granulocyte-macrophage 
colony-stimulating factor/interleukin-3 fusion protein; EPO, erythropoietin; TNC, total nucleated cell; 
ANC, absolute neutrophil count; PLT, platelet; NA, information not available; GVHD, graft-versus-host 
disease. 
Table 3. Published clinical trials of CBT using ex vivo expanded CB 
3.2 Reduced-intensity conditioning regimen 
Myeloablative conditioning (MAC) regimens for allogeneic HSCT have been restricted to 
younger patients without comorbidities, because TRM occurs more frequently among 
elderly patients and those with serious comorbidities. Reduced-intensity conditioning (RIC) 
regimens have emerged as a novel transplantation modality for those patients with the 
expectation of reducing TRM and increasing survival after allogeneic HSCT. This strategy 
was recently expanded for quick use with stem cell sources not only from BM or mobilized 
PB, but also from CB (Barker et al., 2003; Miyakoshi et al., 2004; Chao et al., 2004; Misawa et 
al., 2006; Brunstein et al., 2007; Komatsu et al., 2007; Majhail et al., 2008; Uchida et al., 2008; 
Cutler & Ballen, 2009; Horwitz & Chao, 2010). Several studies have reported on CBT using 
RIC for adult patients with leukemia, and selected studies using mainly single CB unit are 
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detailed in Table 4. The University of Minnesota group initially reported unrelated CBT for 
adults after RIC, demonstrating that 0-2 antigen mismatched CBT was sufficient to engraft 
most adults after RIC and was associated with low incidence of severe acute GVHD (Barker 
et al., 2003). They reported the updated results of this strategy in 110 adult patients with 
hematological disease to confirm the suitability of this strategy (Brunstein et al., 2007). 
Neutrophil recovery was achieved in 92% at the median of 12 days. The incidence of grades 
III to IV acute GVHD was 22%. However, these studies included the results of 
transplantation of both single and double CB grafts, because the target cell dose for the CB 
graft was 3x107cells/kg. Recenly, same group reported the comparative efficacy of CBT after 
RIC relative to MAC in 119 adult patients with AML in CR (complete remission) (Oran et al., 
2011). The incidence of neutrophil recovery at day +42 was higher with RIC (RIC:94% vs 
MAC:82%; p<0.1). Incidence of grades II to IV acute GVHD was decreased (RIC:47% vs 
MAC:67%; p<0.01). Using RIC, 3-year LFS was decreased (RIC:31% vs MAC:55%; p=0.02) 
and 3-year relapse incidence was increased (RIC:43% vs MAC:9%; p<0.01). Two-year TRM 
was similar (RIC:19% vs MAC:27%; p=0.55). In multivariate analysis, RIC recipients and 
those in CR2 with CR1 duration <1 year had higher risk of relapse and poorer LFS with no 
independent predictors of TRM. Further studies are warranted to establish criteria for 
eligible patients and optimal RIC regimens for CBT. 
 
Reference 
Number 
of 
patients 
Conditining 
regimen 
Median 
TNC cell 
dose 
(/kg) 
Median 
CD34+ 
cell 
dose 
(/kg) 
Median 
time to 
ANC≥500
/μl (days)
Incidence 
of grade II-
IV acute 
GVHD (%)
Incidence of 
TRM (year) 
Relapse rate 
(year) 
Probablity 
of OS 
(year) 
Miyakoshi 
et al.,2004 
30 
Flu/Mel/TBI4
Gy 
3.1 0.7 17.5 27 27% (100 days) 10%[3/30pt] 33% (1) 
Chao et 
al.,2004 
13 Flu/CY/ATG 2.1 1.3 12 40%[2/5pt] 31%[4/13pt] 46%[6/13pt] 22% (4) 
Misawa et 
al.,2006 
12 
Flu/CY/TBI3
Gy 
2.5 0.9 17 62.5 50%[6/12pt] 8%[1/12pt] 42% (1) 
Brustein 
et al.,2007* 
110 
(2CB:93) 
(1CB:17) 
CY/Flu/TBI2
Gy 
3.7(2CB)
3.3(1CB)
4.9(2CB)
3.8(1CB)
12 59 26% (3) 31% (3) 45% (3) 
Komatsu 
et al.,2007 
17 Flu/BU 2.6 0.7 18 0 24%[4/17pt] 41%[7/17pt] 
35%[6/17pt] 
(13months) 
Majhail et 
al.,2008 
43 
CY/Flu/TBI2
Gy 
4.0 0.4 NA 49 28%(180 days) NA 34% (3) 
Uchida et 
al.,2008 
70 
Flu/Mel/TBI4
Gy 
2.8 0.8 18 61 53%[37/70pt] 26%[18/70pt] 23% (2) 
CBT indicates cord blood transplantation; Flu, fludarabine; Mel, melphalan; TBI, total body irradiation; 
CY, cyclophosphamide; ATG, antithymocyte globulin; BU, busulfan; TNC, total nucleated cell; ANC, 
absolute neutrophil count; NA, information not available; GVHD, graft-versus-host disease; pt, patients; 
TRM, treatment-related mortality; OS, overall survival. 
*Some results included CBT using double unit cord blood. 
Table 4. Published reports of CBT using reduced-intensity conditioning in adults 
3.3 Transplantation using multiple grafts of cord blood 
Double CBT (dCBT) was initially developed as a strategy to overcome the cell dose 
limitation preventing the number of adults transplanted with single unit CB, and has been 
widely used in United States and Europe. Several studies have reported on double CBT for 
www.intechopen.com
 
Cord Blood Transplantation in Adults with Acute Leukemia 
 
323 
adult patients with acute leukemia (Barker et al., 2005; Ballen et al., 2007; Rodrigues et al., 
2009; MacMillan et al., 2009a; Gutman et al., 2009; Verneris et al., 2009; Cutler et al., 2010; 
Rocha et al., 2010a, 2010b; Brunstein et al., 2010; Delaney et al., 2009; Stanevsky et al., 2010), 
and representative studies are detailed in Table 5. Several studies showed that double CBT 
is associated with a higher incidence of acute GVHD compared with single CBT (sCBT). 
Interestingly,the risk of relapse after double CBT is significantly lower compared with single 
CBT for patients with leukemia in remission, suggesting that a greater GVL effect due to 
HLA disparity for the double CB recipient (Brunstein et al., 2007, 2010; Rodrigues et al.,  
2009; Verneris et al., 2009). On the other hand, neutrophil engraftment and LFS were similar 
for recipients of single or double CB units. Recently, Roche et al. also reported the results of 
single (n=377) and double (n=230) CBT in adult patients with AML or ALL in remission 
(Rocha et al., 2010a). In patients transplanted in CR 1, there were no statistical differences in 
CI of neutrophil recovery (dCBT 78% vs sCBT 82%; p=0.11). Acute GVHD was higher after 
dCBT compared with sCBT (45% vs 27%; p<0.001). At 3 years, relapse incidence was 15% 
after dCBT and 25% after sCBT (p=0.03). Estimated 3 years LFS was 53% after dCBT and  
 
Reference 
Number of 
patients 
Conditioning 
regimen 
Median 
time to 
ANC≥500/μ
l (days) 
Incidence 
of grade 
II-IV 
acute 
GVHD 
(%) 
Incidence of 
TRM (year) 
Relapse rate 
(year) 
Probablity 
of DFS 
(year) 
Barker et 
al.,2005 
23 
CY/TBI13.2G
y 
23 65 22%(6months) NA 57% (1) 
Brunstein et 
al.,2007 
93 
Flu/CY/TBI2
Gy 
12* 62 26%(3)* 31%(3) * 39% (3) 
Ballen et al., 
2007 
21 
Flu/Mel/AT
G 
20 40 19%(6months) 14% [3/21pt] 67% (1) 
Rodrigues et 
al.,2009 
26 MAC,RIC 17 32 31% (1) 13% (1) 57% (1) 
MacMillan et 
al.,2009a 
185 
MAC42%,RIC
58% 
NA 58% 24%(1) NA NA 
Gutman et 
al.,2009** 
31 
CY/TBI12Gy/
Flu 
NA 81 21% (2) 3% (2) 76% (2) 
Verneris et 
al.,2009 
93 
CY/TBI13.2G
y 
25 48 29%(1) 19%(5) 51% (5) 
Cutler et 
al.,2010 
32 
Flu/Mel/AT
G 
21 9 34%(2) 34%(2) 31%(2) 
Rocha et 
al.,2010a 
230 RIC53% 
CR1:78%***
CR2<:85%***
CR1:45 
CR2<:33 
CR1:32%(3) 
CR2<:34%(3) 
CR1:15%(3) 
CR2<:31%(3) 
CR1:53%(3) 
CR2<:35%(3) 
Brunstein et 
al.2010 
128 
CY/TBI12Gy/
Flu 
26 60 34 % (5) 15% (5) 51% (3) 
CBT indicates cord blood transplantation; CB, cord blood; CY, cyclophosphamide; TBI, total body 
irradiation; Flu, fludarabine; Mel, melphalan; ATG, antithymocyte globulin; MAC, myeloablative 
conditioning; RIC, reduced-intensity conditioning; ANC, absolute neutrophil count; NA, information 
not available; CR, complete remission; GVHD, graft-versus-host disease; TRM, treatment-related 
mortality; pt, patients; DFS, disease-free survival. 
*Some results included CBT using single unit cord blood. 
** This study included 27 patients received two units (six of whom had one of the two units CD34+ 
selected and ex vivo expanded) and four received single units. 
***Results were expressed as cumulative incidence of neutrophil recovery. 
Table 5. Published reports of CBT using double units CB in adults 
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39% after sCBT (p=0.09). However, in patients transplanted in CR2 and CR3, estimated 3 
years LFS was 35% after dCBT and 31% after sCBT (p=0.48). These data concluded double 
CBT has extended the use of CBT for patients otherwise not eligible for single CBT and 
importantly is associated with better outcomes in adults with acute leukemia transplanted 
in early phase of the disease. Brunstein et al. reported 536 patients with leukemia who 
underwent transplantation with an HLA allele-matched related donor (MRD, n=204), HLA 
allele-matched unrelated donor (MUD, n=152) or 1-antigen-mismatched unrelated adult 
donor (MMUD, n=52) or 4-6/6 HLA matched double CB (dCB, n=128) graft after 
myeloablative conditioning (Brunstein et al., 2010). All patients received MAC with 
cyclophosphamide (CY) 120 mg/kg and total body irradiation (TBI) 12 to 13.2 Gy with the 
addition of fludarabine (Flu) 75 mg/m2 in recipients of dCBT. LFS at 5 years was similar for 
each donor type (dCB 51%, MRD 33%, MUD 48%, MMUD 38%). The risk of relapse was 
lower in recipients of dCB (15%) compared with MRD (43%), MUD (37%) and MMUD 
(35%), yet nonrelapse mortality was higher for dCB (34%), MRD (24%), and MUD (14%). 
They conclude that LFS after double CBT is comparable with that observed after MRD and 
MUD transplantation. Although clinical experience using double CBT is progressing as 
described above, 1 CB unit ultimately dominates and confers durable engraftment, but little 
is known about the mechanism of the determinants of durable engraftment by 1 CB unit 
after double CBT. More recently, Avery et al. demonstrated that indicators of CB unit 
potency including TNC dose, colony-forming unit (CFU), CD3+, and viable CD34+ cell 
content, predict the dominating unit, but HLA matching does not appear to play a role in 
unit dominance (Avery et al., 2011). 
3.4 Co-transplantation with third party donor 
Fernandez et al. have developed the strategy of single unit CBT with co-infusion of a limited 
number of mobilized HSC (MHSC) from an HLA-mismached third party donor (TPD) 
(Fernández et al., 2003; Magro et al., 2006; Bautista et al., 2009). They reported the updated 
results of this strategy in 55 adult patients with high-risk hematological malignancies 
(Bautista et al., 2009). The median CB cell dose of 2.37x107cells/kg (the median CB CD34+ 
cells of 0.11x106cells/kg) and the median TPD-MHSC CD34+ cells of 2.4x106cells/kg were 
transplanted. The median time to recovery of neutophils and CB derived neutophils as well 
as to complete CB chimerism was 10, 21 and 44 days. Finally, TPD-MHSC derived 
hematopoiesis disappeared completely. The 5 years OS and DFS were 56 % and 47%, 
respectively. This strategies suggested that transient hematopoiesis from TPD-MHSC might 
reduce the incidence of neutropenia-related serious infection, thus leading to the possibility 
of decreased TRM early after CBT in adult patients. 
3.5 Intrabone transplantation 
To improve efficient engraftment possibly due to better stem cell homing to the bone 
marrow, Frassoni et al. reported the phase I/II study of direct intrabone transplantation of 
single unit CB in 32 patients with acute leukemia (Frassoni et al., 2008). Although the 
median transplanted cell dose was 2.6x107cells/kg (range, 1.4-4.2), the median time to 
recovery of neutrophils in 28 patients and platelets in 27 patients was 23 days (range, 14-44) 
and 36 days (range 16-64), respectively. All patients with hematopoietic recovery showed 
complete donor engraftment from 30 days after CBT. No patient developed grades III to IV 
acute GVHD. This preliminary data suggest that direct intrabone CBT overcomes the 
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problem of graft failure even when low numbers of single unit unrelated HLA-mismatched 
CB are transplanted in adults and need to be confirmed in a larger number of adult patients. 
3.6 Improvement of homing capacity 
The interaction of stromal-derived factor-1 (SDF-1)/CXCL12 with CXCR4 mediates the 
homing of HSCs to the BM. CD26, a surface serine dipeptidylpeptidase IV (DPPIV), cleaves 
the amino-terminal dipeptide from some chemokines, including SDF-1. Diprotin A, which is 
inhibitor of CD26 peptidase activity, enhances engraftment of HSCs from CB into nonobese 
diabetic/severe combined immunodeficiency (NOD/SCID) mice (Campbell et al., 2007). 
Based on these data, the clinical trial to look the efficiency of CB engraftment using Diprotin 
A is now warranted. Moreover, several clinical trials should be investigated to answer the 
efficacy of co-infusion of haploidentical MSCs for the enhancement of engraftment and 
prevention of graft failure in CBT (Macmillan et al., 2009b; Gonzalo-Daganzo et al., 2009; 
Bernardo et al., 2011). 
4. Immune therapy using cord blood 
4.1 Immune reconstitution after CBT  
Infection-related mortality is the primary cause of death early after CBT, with most deaths 
occurring in the first 3-6 months after transplant. Komanduri et al. reported prolonged T 
lymphopenia, impaired T cell functional responses to superantigens and cytomegalovirus 
(CMV), thymopoietic failure were important causes of delayed immune reconstitution after 
CBT in adult (Komanduri et al., 2007). For several months, until recovery of the thymus is 
restored to support de-novo T cell generation, protective antiviral immunity depends on the 
activity of postthymic T cells infused within the CB grafts. However, almost all T cells in CB 
grafts are naïve lymphocytes that have been functionally altered by placental factors to 
provide a protective environment during pregnancy. T cells in CB grafts need to undergo in-
vivo priming, T helper (Th)1/T cytotoxic (Tc)1 maturation, and peripheral expansion before 
they can afford immunologic protection. Remarkable immunophenotypic changes are 
notable already in the first 2-3 weeks after CBT. These changes result from apparent 
’homeostatic’ peripheral T cell expansion in the lymphopenic environment (Szabolcs & 
Niedzwiecki, 2007; Szabolcs & Cairo, 2010).  
4.2 Cellular therapy for viral infection or leukemia after CBT 
One of the major limitations of CBT is the lack of donor cells available for 
posttransplantation donor leukocyte infusions (DLI) to boost immunity for severe viral 
infection or induce GVL activity for leukemia relapse, because the initial donor is 
unavailable. Although there was no obvious available source for adoptive cell therapy in the 
setting of CBT, several researches suggest that adoptive immune therapy using CB immune 
cells have the potential to improve the outcomes after CBT (Hanley et al., 2010). 
4.2.1 Cytotoxic T lymphocytes 
Ex vivo generation of T cells from CB naïve T cells has been achieved in several methods 
using CD3/CD28 costimulation, interleukin (IL)-2, and IL-7 (Mazur et al., 2008; Davis et al., 
2010). Moreover, several researchers successfully have generated antigens-specific cytotoxic 
T lymphocytes (CTLs) from CB. Park et al. developed a protocol to in-vitro-prime and 
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expand CMV-specific CTLs from CB (Park et al., 2006). Recently, Hanley et al. reported the 
generation of single cultures of CTLs from CB that are specific for CMV, Epstein-Barr virus 
(EBV) and adenovirus (Adv) (Hanley et al., 2009). The CB CTLs recognized multiple viral 
epitopes, including CD4-restricted Adv-hexon epitopes and immunosubdominant CD4- and 
CD8-restricted CMVpp65 epitopes. A clinical trial using CB derived multivirus specific 
CTLs for prevention and treatment of these virus infection in CB transplant is now 
underway. To generate CB derived T cells recognizing B-lineage ALL because GVT effects 
are largely mediated by CTLs, several researchers developed CB derived T cells are 
expanded and genetically modified to express CD19 chimeric antigen receptors (Serrano et 
al., 2006; Micklethwaite et al., 2010). The genetically modified T-cell clones revealed an 
ability to lyse CD19+ leukemic cells specifically and repetitively.  
4.2.2 NK cell 
NK cells are a subset of lymphocytes with functions associated with innate immunity. NK 
cells also have been found to substantially contribute to GVT effects. Adoptive immune 
therapy with NK cells to treat malignancy is actively being investigated in early phase 
clinical trials. Ruggeri et al. reported the PB derived NK cell alloreactively is capable of 
preventing relapse of AML in the setting of killer immunoglobulin-like receptor (KIR) 
ligand-mismatched haploidentical HSCT (Ruggeri et al., 2002). Two retrospective studies on 
the effects of KIR ligand-mismatching in CBT for leukemia have result in conflicting results. 
Willemze et al. reported that a favourable effect of KIR ligand-mismatching on relapse rate 
and survival (Willemze et al., 2009), whereas Brunstein et al. reported no effect on relapse 
(Brunstein et al., 2009). The impact of KIR ligand-mismatching on relapse after CBT remains 
to be determined. NK cells are present at the similar percentages in both CB and PB. 
However, CB NK cells express a relatively higher percentage of inhibitory receptors, such as 
CD94/NKG2A and KIR (Verneris & Miller, 2009). The expanded CB NK cells exhibit anti 
leukemic activity in mouse model (Xing et al., 2010). Based on these data, the efficiency of 
CB NK cells to treat leukemia relapse is now underway. 
4.2.3 Regulatory T cell 
Regulatory T cells (Tregs) are a suppressive subset of the naturally occurring T cells 
characterized by their constitutive expression of CD4 and the IL-2 receptor α chain (CD25). 
Tregs are also characterized by high levels of the forkhead box protein 3 (FoxP3). Tregs can 
abrogate GVHD in murine models of major histocompatibility complex (MHC) mismatched 
allogeneic HSCT through suppression of alloreactive effector T cells.  In contrast to Tregs 
from PB, Tregs are readily purified from CB. CB Tregs have greater expansion potential 
when compared to PB Tregs (Tolar et al., 2009). Brunstein et al. reported that infusion of ex 
vivo expanded Tregs from CB reduced the incidence of grades II to IV acute GVHD in CBT 
recipients compared with historical controls without Tregs (Brunstein et al., 2011). 
4.2.4 MSCs 
MSCs were initially described as a BM-derived mononuclear cell population adhered to 
plastic with a fibroblast-like morphology, when cultured ex vivo. Thereafter, MSCs can also 
be isolated from CB (Tolar et al., 2009). These cells are capable of differentiation into 
multiple lineages, including bone, cartilage and adipocyte cells in particular. The functional 
aspects of MSCs include tissue repair, hematopoietic engraftment support, immune 
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modulation. Clinical trial studying the effects of BM derived MSCs for the treatment of 
standard therapy-resistant severe GVHD has been initiated recently with promising results 
(Le Blanc et al., 2008). However, whether CB derived MSCs have similar beneficial effects 
for the treatment of severe GVHD is unknown. 
5. Problem of donor cell leukemia 
Donor cell-derived hematological malignancy is a rare complication after allogeneic HSCT. 
Previous studies reported that 0.12-5% of patients developed donor cell leukemia (DCL) 
after allogeneic HSCT (Hertenstein et al., 2005; Flynn & Kaufman, 2007; Wiseman, 2010). 
Several reports demonstrated that donor cell-derived hematological malignancy occurred in 
patients after CBT (Matsunaga et al., 2005; Fraser et al., 2005; Ando et al., 2006; Sevilla et al., 
2006; Mitsui et al., 2007; Nagamura-Inoue et al., 2007; Hamaki et al., 2008; Konuma et al., 
2009b; Crow et al., 2010; Castleton et al., 2010; Ballen et al., 2010; Wang et al., 2011). Ballen et 
al. reported the occurrence of donor-derived hematological malignancies after double CBT 
(Ballen et al., 2010). Sixteen patients developed a second hematological malignancy (both 
cases of MDS/myeloproliferative diseases (MPD) and 14 of the lymphomas) at a median of 
134 days after double CBT. The mechanism for causing DCL after allogeneic HSCT is not 
well understood. The presence of preleukemic clones found only rarely in CB samples might 
contribute to the development of DCL after CBT (Mori et al., 2002). Moreover, various 
factors including impaired tumor surveillance, chronic antigenic stimulation by differences 
between donor and recipient cells, perturbations within the host BM microenvironment, 
premature aging of the donor cells, and the associated chromosomal instability might 
contribute to the development of DCL after allogeneic HSCT (Flynn & Kaufman, 2007; 
Wiseman, 2010). It has been hypothesized that donor cell-derived hematological malignancy 
may be substantially more frequent with a CB source of stem cells (Greaves, 2006). Further 
research and the increasing number of reports will improve understanding of the clinical 
implications of the donor cell-derived hematological malignancies after CBT. 
6. Conclusion 
Clinical results of CBT for acute leukemia have improved recently in adult patients. In 
addition to the potent HSCs in CB, multiple populations of stem cells with stem cell 
properties have been identified from CB and have led to the idea that CB can be used for 
regenerative therapies. In fact, clinical trials are now underway in type 1 diabetes, cerebral 
palsy and peripheral vascular disease. Moreover, recent studies demonstrated that it is 
possible to generate induced pluripotent stem (iPS) cells from human CB (Giorgetti et al., 
2009; Haase et al., 2009; Hu et al., 2011; Broxmeyer et al., 2011). These data offer CB derived 
iPS cells are also considered an ideal source for future regenerative therapies. 
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